Technical Analysis for MESO - Mesoblast Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 2.31 | -4.94% | -0.12 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hammer Candlestick | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Calm After Storm | Range Contraction | -4.94% | |
Outside Day | Range Expansion | -4.94% | |
Wide Bands | Range Expansion | -4.94% | |
Gapped Down | Weakness | -4.94% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -5.33% | |
180 Bullish Setup | Bullish Swing Setup | -5.33% |
Alert | Time |
---|---|
Gap Down Partially Closed | about 21 hours ago |
Gapped Down (Partial) | about 22 hours ago |
Down 5% | about 22 hours ago |
Down 3% | about 22 hours ago |
Fell Below Previous Day's Low | about 22 hours ago |
Get a Trading Assistant
- Earnings date: 02/28/2024
Mesoblast Limited Description
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Stem Cell Bone Cardiovascular Disease Heart Failure Therapeutic Products Hematology Rheumatoid Arthritis Vascular Disease Spine Pharmaceutical Industries Transplantation Bone Marrow Diabetic Nephropathy Congestive Heart Failure Host Disease Skeletal Disorders Spinal Fusion Adult Stem Cell Back Pain Cell Product Graft Versus Host Disease Ischemia Degenerative Disc Disease Inflammatory Conditions Teva Pharmaceutical Industries Mesoblast Cardiac Diseases Musculoskeletal Disorders Regenerative Biomedicine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.24 |
52 Week Low | 1.61 |
Average Volume | 458,898 |
200-Day Moving Average | 3.65 |
50-Day Moving Average | 2.00 |
20-Day Moving Average | 2.20 |
10-Day Moving Average | 2.35 |
Average True Range | 0.18 |
RSI (14) | 56.71 |
ADX | 36.14 |
+DI | 36.20 |
-DI | 15.70 |
Chandelier Exit (Long, 3 ATRs) | 2.64 |
Chandelier Exit (Short, 3 ATRs) | 2.46 |
Upper Bollinger Bands | 2.62 |
Lower Bollinger Band | 1.77 |
Percent B (%b) | 0.64 |
BandWidth | 38.31 |
MACD Line | 0.13 |
MACD Signal Line | 0.11 |
MACD Histogram | 0.0218 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.50 | ||||
Resistance 3 (R3) | 2.49 | 2.41 | 2.47 | ||
Resistance 2 (R2) | 2.41 | 2.37 | 2.42 | 2.46 | |
Resistance 1 (R1) | 2.36 | 2.34 | 2.33 | 2.37 | 2.45 |
Pivot Point | 2.29 | 2.29 | 2.27 | 2.29 | 2.29 |
Support 1 (S1) | 2.24 | 2.24 | 2.20 | 2.25 | 2.17 |
Support 2 (S2) | 2.16 | 2.21 | 2.17 | 2.16 | |
Support 3 (S3) | 2.11 | 2.16 | 2.15 | ||
Support 4 (S4) | 2.12 |